About Contact Us Careers

Rituximab Market Size and Forecast, by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Application (Blood Cancer, Rheumatoid Arthritis, Wegener Granulomatosis) - Growth Trends, Key Players, Regional Analysis 2026-2035

  • Report ID: 3315
  • Published Date: Nov 19, 2025
  • Report Format: PDF, PPT

Rituximab Market Outlook:

Rituximab Market size was over USD 5.11 billion in 2025 and is poised to exceed USD 22.16 billion by 2035, growing at over 15.8% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of rituximab is evaluated at USD 5.84 billion.

rituximab market trends
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

The increasing incidences of non-Hodgkin’s lymphoma (NHL) are expected to boost the market growth of rituximab. As per the American Cancer Society, NHL is one of the most common diseases in the USA. Around 77,200 cases were registered in 2020 in the US, the incidences are anticipated to grow rapidly due to the rising cases of cancer in the region.

In case of an autoimmune disease, the immune system attacks the healthy cells of the body. Thus, the rising prevalence of autoimmune diseases is likely to accelerate the growth of the rituximab market. According to the reports by University of Oxford, about 22 million are affected by autoimmune diseases yearly. These factors are bolstering the market growth of rituximab.

Key Rituximab Market Insights Summary:

  • Regional Insights:

    • By 2035, North America is projected to command a 45% share in the Rituximab Market, sustained by rising government allocations for cancer research and the strong presence of leading pharmaceutical companies.
    • The Asia Pacific region is expected to secure the second-largest position and exhibit a 12.1% growth rate through 2035, supported by expanding disposable incomes, a sizable patient pool, and growing emphasis on healthcare.

  • Segment Insights:

    • By 2035, the hospital pharmacies segment in the Rituximab Market is projected to secure a 39.7% share, supported by expanding global healthcare expenditure, rising patient awareness, and enhanced hospital infrastructure in high-income nations.
    • The blood cancer segment is anticipated to capture a 24% share by 2035, propelled by increasing disease incidence and higher oncology-focused healthcare investment.

  • Key Growth Trends:

    • Increasing Demand for Monoclonal Antibodies
    • Increasing collaborations for the development of new products

  • Major Challenges:

    • High Cost of Rituximab
    • Severe Side Effects

  • Key Players: Amgen Inc, Henlius Biotech, Inc., Nordic Nanovector ASA, Biocon Biologics Ltd, Pfizer Inc., Chugai Pharmaceuticals, Zenyaku Kogyo Co. Ltd, SymBio Pharmaceuticals, Daiichi Sankyo, Kyowa Kirin Co. Ltd.

Global Rituximab Market Forecast and Regional Outlook:

  • Market Size & Growth Projections:

    • 2025 Market Size: USD 5.11 billion
    • 2026 Market Size: USD 5.84 billion
    • Projected Market Size: USD 22.16 billion by 2035
    • Growth Forecasts: 15.8%

  • Key Regional Dynamics:

    • Largest Region: North America (45% Share by 2035)
    • Fastest Growing Region: Asia Pacific
    • Dominating Countries: United States, China, Germany, Japan, United Kingdom
    • Emerging Countries: India, South Korea, Brazil, Australia, Canada

    • Last updated on : 19 November, 2025

Growth Drivers

  • Increasing Demand for Monoclonal Antibodies – rituximab is one of the most common monoclonal antibodies used in the treatment of cancer, cardiovascular diseases and others. Also, the survival rate has increased with the application of rituximab with chemotherapy. In addition to this the rising cases of these diseases are boosting the market growth rapidly.

  • Increasing collaborations for the development of new products – In collaboration with other companies operating in the sector, the companies operating in the biosimilars sector continue to focus on the development of new products. The rituximab biosimilar market has been shaped by innovative partnerships. For example, in May 2020, Teva Pharmaceutical Industries Ltd and Celltrion Healthcare Co. Ltd jointly launched a biosimilar of TruximaNumab injection to treat polyangiitis and Rheumatoid Arthritis in the US market.

  • Investment in the healthcare sector - Over the last 15 years, the U.S. is the world's largest contributor to Global Health funding, and its investment in Global Health has increased substantially over time. Additionally, US healthcare spending increased 2.7% in 2021. The Cancer Moonshot, the US cancer plan, is mobilizing efforts to achieve two very important goals set by the President of the United States: Preventing over four million deaths from cancer within 2047 as well as improving the way people who are affected by cancer experience it. Investment and funding in healthcare is positively driving the growth of rituximab market.

Challenges

  • High-Cost of Rituximab - The major challenge to the growth of the rituximab market over the next few years will be the high costs associated with these biosimilars. Compared to IV biosimilar rituximab, the cost of the subcutaneous option was higher.

  • Severe Side Effects

  • Production Complexities

Rituximab Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Year

2026-2035

CAGR

15.8%

Base Year Market Size (2025)

USD 5.11 billion

Forecast Year Market Size (2035)

USD 22.16 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Rituximab Market Segmentation:

Distribution Channel Segment Analysis

The hospital pharmacies segment in the rituximab market is expected to garner the largest revenue during the forecast period. Due to the growing use of rituximab for cancer therapy in hospitals, the hospital pharmacies segment is expected to account for a total market share of 39.7% by 2035. The dominant position of the sector is expected to be achieved during the forecast period by rising healthcare spending around the world, increased awareness levels for patients, and availability of superior hospital infrastructure in high-income countries.

Application Segment Analysis

The blood cancer segment is expected to hold 24% share of the global rituximab market by 2035. Nearly every 3 minutes, one person in the US is diagnosed with blood cancer. Leukaemia was the sixth most frequent cause of cancer deaths in men from 2013 to 2017 and the seventh most frequent cause in women in the US. Also, the increased funding and investment in healthcare mostly in cancer is driving the growth of the market. The cases associated with blood cancer are expected to increase in the upcoming years due to lifestyle factors which will significantly boost the market growth of rituximab.

Our in-depth analysis of the global market includes the following segments:

     Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

     Application
  • Blood Cancer
  • Rheumatoid Arthritis
  • Wegener’s Granulomatosis
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Rituximab Market - Regional Analysis

North American Market Insights

North America industry is anticipated to dominate majority revenue share of 45% by 2035, In addition, market growth is expected to be fuelled by increased government spending on cancer research as well as the presence of major pharmaceutical companies such as Pfizer Inc., Amgen Inc., and Merck & Co.

APAC Market Insights

The Asia Pacific region is expected to hold the second-largest position in the rituximab market. In view of rising disposable incomes, availability of a large patient population for monoclonal antibody cancer treatments, and increased focus on healthcare, the Asia Pacific region is expected to show the highest growth rate during the forecast period at 12.1%. As well as providing investment opportunities in clinical research, countries such as India and China are expected to have a positive impact on the R&D prospects for monoclonal antibodies.

rituximab market value
Get Strategic Analysis by Region Now: Request Free Sample PDF

Rituximab Market Players:

    • Amgen Inc
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Henlius Biotech, Inc.
    • Nordic Nanovector ASA
    • Biocon Biologics Ltd
    • Pfizer Inc.
    • Chugai Pharmaceuticals
    • Zenyaku Kogyo Co. Ltd,
    • SymBio Pharmaceuticals
    • Daiichi Sankyo
    • Kyowa Kirin Co. Ltd

Recent Developments

  • Nordic Nanovector ASA announced the successful outcomes of the Archer-1 phase B trial for treating second-line follicular lymphoma (2L FL), investing Betalutin (177Lu lilotomab satetraxetan) in combination with rituximab (RTX).
  •  Biocon Biologics Ltd has signed an agreement with the Clinton Health Initiative (CHAI) to expand access to lifesaving cancer biosimilars in over 30 countries in Africa and Asia as a part of the Cancer Access Partnership (CAP).
  • Report ID: 3315
  • Published Date: Nov 19, 2025
  • Report Format: PDF, PPT
  • Explore a preview of key market trends and insights
  • Review sample data tables and segment breakdowns
  • Experience the quality of our visual data representations
  • Evaluate our report structure and research methodology
  • Get a glimpse of competitive landscape analysis
  • Understand how regional forecasts are presented
  • Assess the depth of company profiling and benchmarking
  • Preview how actionable insights can support your strategy

Explore real data and analysis

Download Free Sample Report

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of rituximab is evaluated at USD 5.84 billion.

The global rituximab market size was worth over USD 5.11 billion in 2025 and is poised to grow at a CAGR of around 15.8%, reaching USD 22.16 billion revenue by 2035.

By 2035, North America is projected to command a 45% share in the Rituximab Market, sustained by rising government allocations for cancer research and the strong presence of leading pharmaceutical companies.

Key players in the market include Amgen Inc, Henlius Biotech, Inc., Nordic Nanovector ASA, Biocon Biologics Ltd, Pfizer Inc., Chugai Pharmaceuticals, Zenyaku Kogyo Co. Ltd, SymBio Pharmaceuticals, Daiichi Sankyo, Kyowa Kirin Co. Ltd.

Rituximab Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos